IFM Investors’s Vertex Pharmaceuticals VRTX Stock Holding History

IFM Investors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.7M	Buy	57,713 +6,643	+13%	+$2.94M	0.19%	91
2026 Q1	$22.8M	Buy	51,070 +1,290	+3%	+$602K	0.19%	98
2025 Q4	$22.6M	Buy	49,780 +296	+0.6%	+$128K	0.19%	97
2025 Q3	$19.1M	Sell	49,484 -833	-2%	-$348K	0.17%	104
2025 Q2	$22.4M	Buy	50,317 +1,781	+4%	+$821K	0.21%	91
2025 Q1	$23.5M	Sell	48,536 -195	-0.4%	-$90.9K	0.26%	80
2024 Q4	$19.6M	Sell	48,731 -4,691	-9%	-$2.17M	0.2%	94
2024 Q3	$24.8M	Sell	53,422 -65	-0.1%	-$31.2K	0.24%	78
2024 Q2	$25.1M	Buy	53,487 +1,034	+2%	+$449K	0.25%	74
2024 Q1	$21.9M	Sell	52,453 -213	-0.4%	-$90K	0.24%	80
2023 Q4	$21.4M	Sell	52,666 -277	-0.5%	-$102K	0.26%	78
2023 Q3	$18.4M	Buy	52,943 +1,703	+3%	+$596K	0.24%	82
2023 Q2	$18M	Buy	51,240 +4,102	+9%	+$1.38M	0.24%	82
2023 Q1	$14.9M	Buy	47,138 +1,423	+3%	+$427K	0.23%	89
2022 Q4	$13.2M	Buy	45,715 +1,184	+3%	+$361K	0.22%	97
2022 Q3	$12.9M	Buy	44,531 +601	+1%	+$173K	0.23%	86
2022 Q2	$12.4M	Buy	43,930 +2,199	+5%	+$589K	0.22%	95
2022 Q1	$10.9M	Buy	41,731 +7,534	+22%	+$1.79M	0.17%	117
2021 Q4	$7.51M	Sell	34,197 -403	-1%	-$78.4K	0.14%	140
2021 Q3	$6.28M	Buy	34,600 +2	+0%	+$390	0.13%	150
2021 Q2	$6.98M	Buy	34,598 +5,776	+20%	+$1.21M	0.14%	145
2021 Q1	$6.19M	Buy	28,822 +3,848	+15%	+$845K	0.17%	126
2020 Q4	$5.9M	Buy	24,974 +2,997	+14%	+$688K	0.19%	114
2020 Q3	$5.98M	Buy	21,977 +3,093	+16%	+$853K	0.25%	77
2020 Q2	$5.48M	Sell	18,884 -6,591	-26%	-$1.79M	0.28%	70
2020 Q1	$5.91M	Sell	25,475 -943	-4%	-$216K	0.26%	84
2019 Q4	$5.78M	Sell	26,418 -1,178	-4%	-$238K	0.2%	106
2019 Q3	$4.67M	Buy	27,596 +9,502	+53%	+$1.68M	0.17%	135
2019 Q2	$3.32M	Buy	18,094 +1,229	+7%	+$215K	0.19%	117
2019 Q1	$3.1M	Buy	16,865 +2,180	+15%	+$403K	0.2%	110
2018 Q4	$2.43M	Buy	14,685 +1,330	+10%	+$230K	0.2%	113
2018 Q3	$2.57M	Buy	13,355 +1,954	+17%	+$348K	0.2%	113
2018 Q2	$1.94M	Buy	11,401 +3,525	+45%	+$546K	0.18%	124
2018 Q1	$1.28M	Buy	7,876 +833	+12%	+$136K	0.18%	128
2017 Q4	$1.05M	Buy	7,043 +42	+0.6%	+$6.22K	0.17%	141
2017 Q3	$1.06M	Buy	7,001 +201	+3%	+$30.3K	0.18%	134
2017 Q2	$876K	Buy	6,800 +1,811	+36%	+$218K	0.16%	154
2017 Q1	$546K	Buy	4,989 +1,833	+58%	+$161K	0.14%	178
2016 Q4	$233K	Buy	+3,156	New	+$257K	0.11%	254

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

MLL

Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return

IFM Investors's VRTX Position: Q2 2026 in Review

IFM Investors increased its Vertex Pharmaceuticals (VRTX) stake by 13% in Q2 2026, buying an estimated $2.94M and bringing the position to 57,713 shares worth $28.7M. The position accounts for 0.19% of the portfolio, ranked #91.

IFM Investors first reported a position in VRTX in Q4 2016 and has held it in 39 quarters since. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

IFM Investors held 57,713 shares of Vertex Pharmaceuticals worth $28.7M as of Q2 2026.
IFM Investors bought 6,643 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.94M.
Vertex Pharmaceuticals made up 0.19% of IFM Investors's portfolio in Q2 2026, its #91 holding.
IFM Investors first reported a position in Vertex Pharmaceuticals in Q4 2016 and has held it in 39 quarters since.
334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on IFM Investors's 13F filing for Q2 2026, filed 21 Jul 2026.